Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.52 |
| ▸ | ERN1 | O75460 | 13/20 | 0.50 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.46 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9353882 | 0.85 | PADI4 (0.50) | PADI4ERN1TRIM24TRIM33MCL1 | |
| SCHEMBL8416094 | 0.85 | LMNA (0.50) | PADI4ERN1TRIM24TRIM33MCL1 | |
| SCHEMBL22721454 | 0.83 | ERN1 (0.52) | PADI4ERN1TRIM24TRIM33 | |
| SCHEMBL8974313 | 0.82 | HTT (0.57) | PADI4ERN1TRIM24TRIM33MCL1 | |
| SCHEMBL7918991 | 0.82 | MEN1 (0.53) | PADI4ERN1TRIM24TRIM33MEN1 | |
| SCHEMBL19792630 | 0.82 | ERN1 (0.50) | PADI4ERN1TRIM24TRIM33MEN1 | |
| SCHEMBL9721295 | 0.80 | HPGD (0.46) | PADI4ERN1TRIM24TRIM33MEN1 | |
| SCHEMBL31339466 | 0.80 | HPGD (0.46) | PADI4ERN1TRIM24TRIM33MEN1 | |
| SCHEMBL28293873 | 0.80 | PADI4 (0.46) | PADI4ERN1TRIM24TRIM33MCL1 | |
| SCHEMBL5663542 | 0.80 | PTPN1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1304924-A2 | COMPOSITIONS FOR REPELLING CRAWLING INSECTS | Bayer Aktiengesellschaft (DE) | 2003-05-02 | — | — | EP | disclosed |
| US-20020094993-A1 | Compositions for repelling crawling insects | S.C. JOHNSON & SON, INC. | 2002-07-18 | — | — | US | disclosed |
| WO-2002005646-A2 | COMPOSITIONS FOR REPELLING CRAWLING INSECTS | S.C. JOHNSON & SON, INC. (US) (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094993-A1 | Compositions for repelling crawling insects | ACHE, DDT, GAP43 | PADI4 4800/4885ERN1 4751/4885TRIM24 4167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.